Healthcare
Biotech Moves Smarter: IDDI Powers Data-Driven Drug Innovation
Smaller pharma companies are accelerating drug development by leveraging advanced data analytics to streamline trials and regulatory pathways
Key takeaways
IDDI provides personalized, hands-on clinical trial design and data support tailored to small and mid-size biotech companies that may be deprioritized by larger CROs.
IDDI's spin-off 'One to Treat' pioneers multi-endpoint trial design to capture richer, patient-centered outcomes in oncology and rare diseases.
Jeremy Edwards is focused on building U.S. brand awareness for IDDI and introducing differentiated messaging in a traditionally conservative industry.
As biotech innovation accelerates, small and mid-size pharmaceutical companies are becoming key players in bringing new treatments to market. Yet many of these organizations face steep challenges when navigating clinical trial design, regulatory approval, and data integrity. According to a McKinsey Global Institute report, industries like biotech could help generate up to $50 trillion in global revenue by 2040, underscoring their massive economic and social impact.
Industries like biotech could help generate up to $50 trillion in global revenue by 2040, underscoring their massive economic and social impact.
So how can niche research partners like IDDI help smaller biotech companies overcome these hurdles and compete in a market dominated by major pharmaceutical brands?
In this episode of While You Were Working, host Chip Rosales, Managing Partner at Rogue Marketing, speaks with Jeremy Edwards, Chief Commercial Officer at IDDI. The conversation explores how Edwards is helping IDDI expand its U.S. footprint, how the company differentiates itself in a saturated CRO market, and what innovations like AI and creative trial design mean for the future of clinical research.
Key Highlights from the Conversation:
- Supporting Small Biotech Companies: IDDI specializes in providing hands-on, personalized trial design and data support for small and mid-size biotech firms, helping them avoid getting lost among larger CRO priorities.
- Creative Statistical Methods & Innovation: With its spin-off "One to Treat," IDDI is pioneering multi-endpoint trial design to capture richer, more patient-centered outcomes in areas like oncology and rare diseases.
- Market Expansion & Differentiation: Edwards' top priorities include building U.S. brand awareness, leveraging therapeutic area expertise, and introducing differentiated messaging in a traditionally conservative industry. Edwards' top priorities include building U.S. brand awareness, leveraging therapeutic area expertise, and introducing differentiated messaging in a traditionally conservative industry.
Jeremy Edwards is a seasoned executive in clinical research and digital health, with over two decades of experience leading commercial strategy, business development, and international expansion for CROs and biotech service organizations. He currently serves as Chief Commercial Officer at IDDI, where he focuses on clinical trial design innovation and expanding the company's U.S. presence. Previously, Edwards held senior leadership roles at YPrime, Xperiome, and AMRA Medical, consistently driving growth through strategic partnerships, rare disease expertise, and technology-enabled patient engagement.
About the author
For nearly 20 years, Chip has been bending the rules, asking the question “why” and looking for innovative ways to get companies noticed. This has led to a number of corporate executive roles with opportunities to lead digital marketing teams, uncover emotional differentiators and build/amplify brands. In 2009, he left corporate America to build a strategy agency of his own. You can find Chip keepin’ it Rogue performing on stages around the Dallas metroplex and rooting on the UT Longhorns… whether they’re winning or not.
